Angle Plc has raised £12.2 million, before expenses, to finance the purchase of assets from Canada-based Axela Inc that will broaden its liquid biopsy capabilities enabling it to both harvest circulating tumour cells from patients and analyse them for gene expression.
Finland-based Faron Pharmaceuticals Oy is proposing to raise up to £10 million, before expenses, in a private share placement to support the late-stage development and commercialisation of its product for acute respiratory distress syndrome Traumakine.
The British specialty pharma company BTG Plc has broadened its portfolio of treatments for hospital procedures with the acquisition of Roxwood Medical Inc of Redwood City, California. The deal is valued at up to $80 million.
Ablynx NV has filed registration documents with the US Securities and Exchange Commission to raise up to $150 million in an initial public offering of its shares on Nasdaq. Based in Ghent, Belgium, Ablynx went public on Euronext in Brussels in 2007.
Evotec AG has made a €15 million equity investment in Exscientia Ltd which is developing artificial intelligence technologies to aid drug discovery. The German company already has a research collaboration with Exscientia dating from 2016.
UK-based Autolus Ltd has secured $80 million in Series C capital from new and existing investors to advance the development of its engineered T cell therapies for cancer. The new investors include US-based Cormorant Asset Management and Nextech Invest of Switzerland.
The Bill & Melinda Gates Foundation is to invest up to $40 million in Immunocore Ltd to support the development of the company’s T cell receptor technology (TCR) for infectious disease. The UK company already has partnerships exploring TCRs against cancer.
The Italian gene therapy company, Genenta Science srl, has raised €7 million in a Series B financing round to support development of a second tumor indication for its technology platform in addition to multiple myeloma. The funding was announced on 13 September.
Merck & Co Inc is to acquire Rigontec GmbH of Germany in order to strengthen its portfolio of immuno-oncology compounds led by pembrolizumab. Rigontec has assets that target the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system.
Nightstar Therapeutics Ltd plans to raise up to $86 million in an initial public offering (IPO) of its shares on Nasdaq to advance its portfolio of gene therapies to treat rare inherited retinal diseases. A registration document was filed with the US Securities and Exchange Commission on 31 August.